Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hCT-MSC in COVID-19 Related ARDS
NCT04399889Phase 2Terminated
- Sponsor
- Joanne Kurtzberg
- Start
- Jun 2020
- Primary completion
- Feb 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of wharton's jelly mesenchymal stromal cells in acute respiratory distress syndrome (ARDS), sponsored by Joanne Kurtzberg. Started Jun 2020; status: terminated.
02
Drugs
wharton's jelly mesenchymal stromal cells
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04399889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04399889.